| P2093 | author name string | Qiang Yang | |
| | Jing Cai | |
| | Yan Fang | |
| | Ying Zhu | |
| | Zehua Wang | |
| | Xiaoqing Yi | |
| | Linjuan Xu | |
| | Huijuan Tang | |
| P2860 | cites work | Bias in meta-analysis detected by a simple, graphical test | Q24685585 |
| | Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints | Q27860640 |
| | Quantifying heterogeneity in a meta-analysis | Q27860672 |
| | Meta-analysis in clinical trials | Q27860779 |
| | Statistical aspects of the analysis of data from retrospective studies of disease | Q27860916 |
| | Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting | Q27861077 |
| | Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths | Q28241157 |
| | The biology and clinical relevance of the PTEN tumor suppressor pathway | Q28272157 |
| | Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN | Q28513537 |
| | The phosphatidylinositol 3-Kinase AKT pathway in human cancer | Q29547860 |
| | Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study | Q33348987 |
| | PTEN, a unique tumor suppressor gene | Q33974014 |
| | Microarray-based oncogenic pathway profiling in advanced serous papillary ovarian carcinoma | Q33974923 |
| | BRCAness profile of sporadic ovarian cancer predicts disease recurrence | Q34130956 |
| | PI3K-Akt pathway: its functions and alterations in human cancer | Q34362034 |
| | Prognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer | Q34616626 |
| | Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome | Q35032772 |
| | PI3K/Akt signalling pathway and cancer. | Q35692250 |
| | PI 3-kinase, Akt and cell survival | Q35812415 |
| | Molecular prognostic markers in ovarian cancer: toward patient-tailored therapy. | Q36412960 |
| | Evaluation of the quality of prognosis studies in systematic reviews | Q36426632 |
| | The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer | Q36785983 |
| | PTEN and the PI3-kinase pathway in cancer | Q37259680 |
| | High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia | Q37268926 |
| | Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features | Q37982940 |
| | Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma | Q39330252 |
| | Estrogen and progestin regulate metastasis through the PI3K/AKT pathway in human ovarian cancer | Q39925814 |
| | Activation of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma | Q39968868 |
| | Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer | Q40673230 |
| | PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells | Q42811887 |
| | Akt activation by growth factors is a multiple-step process: the role of the PH domain | Q42827602 |
| | Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma | Q43479718 |
| | PIK3CA overexpression is a possible prognostic factor for favorable survival in ovarian clear cell carcinoma | Q44600214 |
| | Growth suppression of human ovarian cancer cells by adenovirus-mediated transfer of the PTEN gene | Q45864448 |
| | Prognostic value and clinicopathological significance of p53 and PTEN in epithelial ovarian cancers | Q46159400 |
| | Expression of PTEN in ovarian epithelial tumors and its relation to tumor behavior and growth. | Q53612288 |
| | Alteration and clinical relevance of PTEN expression and its correlation with survivin expression in epithelial ovarian tumors. | Q53633276 |
| | PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients. | Q54506179 |
| | PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death | Q73229813 |
| | PTEN mutation, expression and LOH at its locus in ovarian carcinomas. Relation to TP53, K-RAS and BRCA1 mutations | Q79772653 |
| | Prognostic value of PIK3CA and phosphorylated AKT expression in ovarian cancer | Q80010199 |
| | Prognostic implications of the nuclear localization of Y-box-binding protein-1 and CXCR4 expression in ovarian cancer: their correlation with activated Akt, LRP/MVP and P-glycoprotein expression | Q80216629 |
| | Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas | Q81278294 |
| | PTEN promoter methylation and LOH of 10q22-23 locus in PTEN expression of ovarian clear cell adenocarcinomas | Q82600359 |
| | Increased staining for phosphorylated AKT and nuclear factor-kappaB p65 and their relationship with prognosis in epithelial ovarian cancer | Q82891685 |
| | Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer | Q84596917 |
| P433 | issue | 5 | |
| P921 | main subject | ovarian cancer | Q172341 |
| | meta-analysis | Q815382 |
| P304 | page(s) | 528-535 | |
| P577 | publication date | 2014-04-09 | |
| P1433 | published in | Oncologist | Q2122327 |
| P1476 | title | The role of the PTEN/PI3K/Akt pathway on prognosis in epithelial ovarian cancer: a meta-analysis | |
| P478 | volume | 19 | |